METHODS OF TREATING DISEASES WHICH ARE MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE CELLS

• US 20090280121A1
• Filed: 07/02/2009
• Published: 11/12/2009
• Est. Priority Date: 02/14/2005
• Status: Abandoned Application

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Bilsborough, Janine, Gross, Jane A., Leung, Donald Y.M.
• Application Number:
  US12/497,383
• Publication Number:
  US 20090280121A1
• Time in Patent Office: Days
• US Class Current: 424/135.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 49/0008 Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
• CPC Class Codes: A61K 49/006 Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/52 Cytokines; Lymphokines; Interferons
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: G01N 33/505 involving T-cells
• CPC Class Codes: G01N 33/6869 : Interleukin
• CPC Class Codes: G01N 33/6881 : from skin

Abstract

The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.

Claims

1. A method of treating a skin disorder characterized by cutaneous lymphocyte antigen positive T cells comprising administering an antibody or antibody fragment to a mammal with the skin disorder wherein the antibody or antibody fragment specifically binds to the polypeptide comprising the amino acid sequence as shown in SEQ ID NO:

2, wherein the skin disorder is selected from Drug induced delayed type cutaneous allergic reactions;

Toxic epidermal necrolysis;

Cutaneous T cell Lymphoma;

Bullous pemphigoid;

Alopecia aereata;

Vitiligo;

Acne Rosacea;

Prurigo nodularis; and

Herpes simplex virus and whereby the skin disorder is improved, inhibited, or reduced.

2. The method according to claim 1, wherein the mammal is a human.

3. The method of claim 1, wherein the antibody or antibody fragment is monoclonal.

4. The method of claim 1, wherein the antibody or antibody fragment is neutralizing.

5. The method of claim 1, wherein in the antibody or antibody fragment is (a) a murine monoclonal antibody, (b) a humanized antibody derived from (a), (c) a chimeric antibody fragment, (d) a human monoclonal antibody;

or (e) a single chain antibody.

6. The method of claim 1, wherein the antibody fragment is selected from the group consisting of:

a) a Fab fragment;

b) a Fab′

fragment;

c) a Fv fragments;

d) a F(ab′

)2 fragment; and

e) a single chain antibody fragment.

7. A method of improving, inhibiting, or reducing at least one symptom associated with a skin disorder characterized by cutaneous lymphocyte antigen positive T cells comprising administering an antibody or antibody fragment to a mammal wherein the at least one symptom is selected from the group consisting of:

a) blisters;

b) acne;

c) lichenified or excoriated nodules; and

d) erythematopapular skin lesions and hypereosinophilia

and wherein the antibody or antibody fragment specifically binds to the polypeptide comprising the amino acid sequence as shown in SEQ ID NO;

2.

8. The method of claim 7, wherein the blister are selected from the group consisting of:

a) epidermal blisters infiltrated with lymphocytes that are cutaneous lymphocyte antigen positive T cells;

b) subepidermal blisters with a dermal infiltrate of neutrophils and eosinophils.

9. The method of claim 8, wherein the blisters are a symptom of Toxic epidermal necrolysis.

10. The method of claim 8, wherein the blisters are a symptom of Bullous pemphigoid.

11. The method of claim 7, wherein the acne is a symptom of Acne vulgaris or Acne rosacea.

12. The method of claim 7, wherein the lichenified or excoriated nodules are a symptom of Prurigo nodularis.

13. The method of claim 7, wherein the erythematopapular skin lesions and hypereosinophilia are symptoms of a viral infection.

14. The method of claim 7, wherein the antibody or antibody fragment is monoclonal.

15. The method of claim 7, wherein the antibody or antibody fragment is neutralizing.

16. The method of claim 9, wherein in the antibody or antibody fragment is (a) a murine monoclonal antibody, (b) a humanized antibody derived from (a), (c) a chimeric antibody fragment, (d) a human monoclonal antibody;

or (e) a single chain antibody.

17. The method of claim 7, wherein the antibody fragment is selected from the group consisting of:

a) a Fab fragment;

b) a Fab′

fragment;

c) a Fv fragments;

d) a F(ab′

)2 fragment; and

e) a single chain antibody fragment.